Aura Biosciences

With an initial focus on ocular oncology, Aura is advancing a platform to target solid tumors, using virus-like particles, that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates. We worked with Aura to develop a site that presents their story and their commitment to patients with few options for treatment.
Aura became a public company in 2022 and we supported that effort with an investor site design, graphics for the S1, and a video for the NASDAQ tower in Times Square.


Alcyone is creating next-generation precision gene-based therapies for complex neurological conditions. The company integrates innovation in neuroscience, precision dosing platforms, and manufacturing capabilities to deliver transformative therapies to patients. We worked with Alcyone to 
communicate the breadth of their CNS therapeutic approaches combined with a differentiated and effective delivery system through the development of a variety of corporate materials including a comprehensive company website, coupled with the development of a set of infographics to show each scientific area. We also developed a coordinating stationery system, corporate presentation templates, a scientific poster and presentation set and overall brand standard guide to assist the corporate communications team in overseeing all materials across the three US locations.